Common Prescription Pattern of Antiplatelet and Anticoagulant Drugs in The Management of Cardiovascular Diseases

Cardiovascular diseases (CVD's) are among the leading cause of deathworldwide as well as a major blockade to sustainable humandevelopment.1 According to the world health organization (WHO), it is among the leading causes of morbidity and mortality in India with an estimated 17.7 million deaths per year.2 Anticoagulants are among the most essential life‐saving drugs that are generally used incardiology for the prevention and treatment of many CVD such asischemic heart disease, left ventricular dysfunction, acute coronarysyndrome, valve abnormalities, Atrial fibrillation, deep vein thrombosis, and pulmonary embolism.By slowing the pace of fibrin synthesis, these medications avoid embolic consequences and thrombus extension.drugs given orally (usually for long-term therapy) or parenterally (for the prevention and commencement of treatment of thrombosis as well as other surgical procedures) are the most frequently implicated drugs that cause adverse drug reactions (ADRs) in hospitalized patients. Elderly patients are particularly vulnerable to anticoagulant-associated ADRs, including ecchymosis, epistaxis, hematuria, gastrointestinal (GI) bleeding, thrombocytopenia, osteoporosis, and hypersensitivity reaction. Antiplatelet medications, namely aspirin and P2Y12 receptor antagonists, have considerably decreased the morbidity and mortality linked to arterial thrombosis in recent decades. Numerous clinical trials evaluating their safety and effectiveness in diverse clinical contexts have demonstrated antithrombotic efficacy, and their pharmacological properties, such as pharmacokinetic/pharmacodynamic profiles, have been well investigated.